<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg"/></p>
<p>三個目標產品概況（TPPs）包括關於新治療方法開發的具體指導，為創新提供了一個發展框架。來源：Prrrettty/Shutterstock.com。</p>
<p>世界衞生組織（WHO）已概述了針對三種優先感染的期望抗菌特性，作為引導研究開發急需抗生素的一部分。</p>
<p>WHO 發佈的三個目標產品概況（TPPs）包括關於新治療方法開發的具體指導，為創新提供了一個發展框架。這些新的 TPPs 與該機構的細菌優先病原體名單一致，旨在促進公共和私營部門合作伙伴之間的合作，以激勵並降低與重大醫療負擔感染的研究和開發相關的風險。</p>
<h3>深入瞭解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - BWC-0977 在阿克曼菌感染中的應用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>報告</p>
<h4>LOA 和 PTSR 模型 - BWC-0977 在炭疽桿菌感染中的應用</h4>
<h5>深入瞭解 GlobalData</h5>
<p>商業智能的黃金標準。</p>
<p>瞭解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>發現高效的 B2B 營銷</h4>
<p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
<p>瞭解更多</p>
<p>世界衞生組織將嚴重多重耐藥（MDR）陰性革蘭氏菌感染、免疫抑制和危重病患者的嚴重陽性革蘭氏菌感染以及細菌性腦膜炎列為三項全球創新優先事項。開發更好的抗生素將有助於解決全球高風險人羣中的嚴重血流感染和尿路感染、肺炎和中樞神經系統炎症。細菌性腦膜炎尤其危險——受影響者中大約每六人就有一人死亡。</p>
<p>儘管根據 WHO 的抗菌素 2025 報告，約有 90 種新的抗菌劑正在進行臨牀前或臨牀開發，但很少有臨牀候選藥物針對細菌優先病原體。該機構認為，甚至更少的藥物被視為 “創新”。</p>
<p>WHO 抗微生物耐藥性主任 Yvan Hutin 博士表示：“科學界近年來開發並批准了新的抗生素。這是好事，但不幸的是，無法趕上不斷演變的耐藥細菌，尤其是那些最令人擔憂的細菌。”</p>
<p>“我們需要一個可靠的管道，提供創新、可負擔且所有需要的人都能獲得的新抗菌劑。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 戰略情報</p>
<h1>美國關税正在變化 - 你會反應還是預測？</h1>
<p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
<p>來自 GlobalData</p>
<p>瞭解更多關於戰略情報</p>
<h2>抗微生物耐藥性（AMR）的健康負擔</h2>
<p>抗微生物耐藥性（AMR）是指細菌、病毒、真菌和寄生蟲進化以抵抗抗微生物藥物。在耐藥細菌的情況下，抗生素可能失效。2023 年，全球約六分之一的實驗室確認的細菌感染是由耐藥細菌引起的。估計 2019 年，細菌抗微生物耐藥性（AMR）直接導致了 127 萬人死亡，這是最後一年有此類數據可用的年份。預計如果不採取行動，例如開發更先進的抗生素，到 2050 年 AMR 將導致 1000 萬人死亡。</p>
<p>2025 年 10 月，WHO 要求其成員國、捐助者和合作夥伴加強對抗 AMR 的協調響應。當時，衞生機構要求每兩年提供 8500 萬美元以幫助應對這一公共衞生問題。目前尚不清楚 美國退出 WHO 將如何具體影響 AMR，但專家普遍認為，該機構的全球健康努力將受到阻礙。美國曆來是 WHO 最大的捐助國。</p>
<p>其他地區已建立自己的運動。例如，英國 承諾 210 百萬英鎊（約 267.7 百萬美元） 以幫助追蹤亞洲和非洲的抗生素耐藥細菌。這項投資支持弗萊明基金的全球抗微生物耐藥性監測（AMR）計劃，旨在在危險超級細菌到達英國之前識別它們。2025 年 9 月，歐盟啓動了一項 2.53 億歐元的倡議，以應對 AMR。</p>

<p>世界衞生組織（WHO）發佈了三種優先感染的目標產品輪廓（TPPs），以指導急需抗生素的開發。這些 TPPs 旨在促進公共和私營部門之間的合作，以應對嚴重的多重耐藥感染和細菌性腦膜炎。儘管目前有 90 種新的抗菌藥物在開發中，但很少有針對優先病原體。WHO 強調需要創新且價格合理的抗生素來對抗抗微生物耐藥性（AMR），該問題在 2019 年導致了 127 萬人死亡，預計如果不採取行動，到 2050 年將導致 1000 萬人死亡</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/shutterstock_1957130641-430x241.jpg"/></p>
<p>The three Target Product Profiles (TPPs) include specific guidance on the development of new treatments, providing a developmental framework to align innovation. Credit: Prrrettty/Shutterstock.com.</p>
<div class="lb-trans"><p>三個目標產品概況（TPPs）包括關於新治療方法開發的具體指導，為創新提供了一個發展框架。來源：Prrrettty/Shutterstock.com。</p>
</div><p>The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to direct research towards developing urgently needed antibiotics.</p>
<div class="lb-trans"><p>世界衞生組織（WHO）已概述了針對三種優先感染的期望抗菌特性，作為引導研究開發急需抗生素的一部分。</p>
</div><p>The three Target Product Profiles (TPPs) published by WHO include specific guidance on the development of new treatments, providing a developmental framework to align innovation. The new TPPs are in line with the agency’s bacterial priority pathogen list, aiming to foster collaboration between public and private sector partners to incentivise and reduce the risks associated with research and development for infections with significant healthcare burden.</p>
<div class="lb-trans"><p>WHO 發佈的三個目標產品概況（TPPs）包括關於新治療方法開發的具體指導，為創新提供了一個發展框架。這些新的 TPPs 與該機構的細菌優先病原體名單一致，旨在促進公共和私營部門合作伙伴之間的合作，以激勵並降低與重大醫療負擔感染的研究和開發相關的風險。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入瞭解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - BWC-0977 in Acinetobacter Infections</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BWC-0977 在阿克曼菌感染中的應用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>報告</p>
</div><h4>LOA and PTSR Model - BWC-0977 in Bacillus anthracis Infections</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - BWC-0977 在炭疽桿菌感染中的應用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入瞭解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商業智能的黃金標準。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>發現高效的 B2B 營銷</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>結合商業智能和編輯卓越，覆蓋 36 個領先媒體平台的專業人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>瞭解更多</p>
</div><p>Severe multidrug-resistant (MDR) gram-negative infections, severe gram-positive infections in immunosuppressed and critically ill patients, and bacterial meningitis have been picked by WHO as three global priorities for innovation. Developing better antibiotics for these would help address severe bloodstream and urinary tract infections, pneumonia and central nervous system inflammations in at-risk populations worldwide. Bacterial meningitis remains particularly dangerous – of those affected, approximately one person in six dies.</p>
<div class="lb-trans"><p>世界衞生組織將嚴重多重耐藥（MDR）陰性革蘭氏菌感染、免疫抑制和危重病患者的嚴重陽性革蘭氏菌感染以及細菌性腦膜炎列為三項全球創新優先事項。開發更好的抗生素將有助於解決全球高風險人羣中的嚴重血流感染和尿路感染、肺炎和中樞神經系統炎症。細菌性腦膜炎尤其危險——受影響者中大約每六人就有一人死亡。</p>
</div><p>Despite 90 new antibacterial agents being in preclinical or clinical development across various infections, as per the WHO’s antibacterial 2025 report, few clinical candidates target bacterial priority pathogens. The agency considers even a smaller amount as ‘innovative’.</p>
<div class="lb-trans"><p>儘管根據 WHO 的抗菌素 2025 報告，約有 90 種新的抗菌劑正在進行臨牀前或臨牀開發，但很少有臨牀候選藥物針對細菌優先病原體。該機構認為，甚至更少的藥物被視為 “創新”。</p>
</div><p>Dr Yvan Hutin, director of antimicrobial resistance at WHO, said: “The scientific community has developed and approved new antibiotics in recent years. This is good, but unfortunately not sufficient to catch up with evolving drug-resistance bacteria, especially against those of greatest concern.</p>
<div class="lb-trans"><p>WHO 抗微生物耐藥性主任 Yvan Hutin 博士表示：“科學界近年來開發並批准了新的抗生素。這是好事，但不幸的是，無法趕上不斷演變的耐藥細菌，尤其是那些最令人擔憂的細菌。”</p>
</div><p>“We need a reliable pipeline with new antibacterial agents that are innovative, affordable and accessible to all those who need them.”</p>
<div class="lb-trans"><p>“我們需要一個可靠的管道，提供創新、可負擔且所有需要的人都能獲得的新抗菌劑。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 戰略情報</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美國關税正在變化 - 你會反應還是預測？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要讓政策變化讓你措手不及。通過實時數據和專家分析保持主動。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>來自 GlobalData</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>瞭解更多關於戰略情報</p>
</div><h2>AMR’s health burden</h2>
<div class="lb-trans"><h2>抗微生物耐藥性（AMR）的健康負擔</h2>
</div><p>Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, and parasites evolve to withstand antimicrobial medicines. In the case of resistant bacteria, antibiotics can be rendered ineffective. In 2023, approximately one in six laboratory-confirmed bacterial infections worldwide were caused by bacteria resistant to antibiotics. It is estimated that bacterial antimicrobial resistance (AMR) was directly responsible for 1.27 million global deaths in 2019, the last year data of this kind is available. It is forecast that AMR will cause ten million deaths by 2050 unless action, such as developing more advanced antibiotics, is taken.</p>
<div class="lb-trans"><p>抗微生物耐藥性（AMR）是指細菌、病毒、真菌和寄生蟲進化以抵抗抗微生物藥物。在耐藥細菌的情況下，抗生素可能失效。2023 年，全球約六分之一的實驗室確認的細菌感染是由耐藥細菌引起的。估計 2019 年，細菌抗微生物耐藥性（AMR）直接導致了 127 萬人死亡，這是最後一年有此類數據可用的年份。預計如果不採取行動，例如開發更先進的抗生素，到 2050 年 AMR 將導致 1000 萬人死亡。</p>
</div><p>In October 2025, the WHO asked its member states, donors and partners to strengthen a coordinated response against AMR. At the time, the health authority was asking for $85m every two years to help fight the public health issue. It is unclear how the US’s departure from WHO will affect AMR specifically, but experts generally believe that global health efforts at the agency will be hampered. The US has historically been the WHO’s largest donor.</p>
<div class="lb-trans"><p>2025 年 10 月，WHO 要求其成員國、捐助者和合作夥伴加強對抗 AMR 的協調響應。當時，衞生機構要求每兩年提供 8500 萬美元以幫助應對這一公共衞生問題。目前尚不清楚 美國退出 WHO 將如何具體影響 AMR，但專家普遍認為，該機構的全球健康努力將受到阻礙。美國曆來是 WHO 最大的捐助國。</p>
</div><p>Other regions have established their own campaigns. The UK, for example, pledged £210m ($267.7m) to help track antibiotic-resistant bacteria across Asia and Africa. The investment, which supports The Fleming Fund’s global antimicrobial resistance surveillance (AMR) programme, aims to identify dangerous superbugs before they arrive in the UK. In September 2025, the European Union launched a €253m initiative to combat AMR.</p>
<div class="lb-trans"><p>其他地區已建立自己的運動。例如，英國 承諾 210 百萬英鎊（約 267.7 百萬美元） 以幫助追蹤亞洲和非洲的抗生素耐藥細菌。這項投資支持弗萊明基金的全球抗微生物耐藥性監測（AMR）計劃，旨在在危險超級細菌到達英國之前識別它們。2025 年 9 月，歐盟啓動了一項 2.53 億歐元的倡議，以應對 AMR。</p>
</div>

世界衞生組織將抗生素的開發重點放在優先病原體上